The Global Impact of NICE Decision Outcomes in Health Technology Assessment

By Staff Writer

September 27, 2023

The English National Institute for Health and Care Excellence (NICE) is a key player in Health Technology Assessment (HTA) worldwide. A report from the Office of Health Economics (OHE) explored NICE’s decision outcomes and their effects on HTA in 12 other countries.

Data showed that NICE decisions are issued relatively quickly, often favouring positive outcomes. However, NICE frequently issued “optimised decisions,” recommendations for using an intervention in a smaller population than licensed but with more favourable cost-effectiveness evidence.

The report also found that NICE’s decisions have a global impact. But, the underlying factors may be more influential than individual technology decisions. NICE’s influence often comes from factors like its reputation as a methods innovator, its decision speed, and the accessibility of its guidance. 

NICE decisions have varying degrees of influence on HTA bodies across different countries:

  • In South Korea, NICE’s decisions significantly impact the Health Insurance Review and Assessment Service (HIRA), with external stakeholder groups pressuring HIRA to follow positive NICE recommendations. 
  • In Brazil, NICE’s decisions also have a strong influence on the National Committee for Health Technology Incorporation (Conitec). 
  • In Poland, positive NICE decisions do not greatly impact local reimbursement decisions, but negative decisions or issues with the economic model require further validation. 
  • In Sweden, the Dental and Pharmaceutical Benefits Agency (TLV) considers NICE’s guidance but makes independent decisions. 
  • In Japan, NICE’s decisions are requested by the Central Social Insurance Medical Council (Chuikyo), but their use and influence are unclear. 
  • In Italy, the Italian Medicines Agency (AIFA) does not usually consider NICE’s decisions but may refer to technical points raised during NICE’s appraisal for complex cases. 
  • In Saudi Arabia and the UAE, the Ministry of Health may look at NICE’s decision for context, and in Israel, NICE’s decisions serve as a reference. 


While positive NICE decisions are associated with positive outcomes in other countries, negative decisions stand out. Other HTA agencies are less willing to go beyond binary decision outcomes, making NICE’s negative decisions more noticeable.

The future impact of NICE on the global HTA landscape might change due to increased collaborations between HTA agencies and post-Brexit activities.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...